Targeting ClpP Rewires the Metabolic-Immune Axis in Acute Myeloid Leukemia.

ClpP agonist IMP125 rewires the metabolic-immune axis in AML, reducing tumor oxygen consumption and enhancing T-cell function.

• Why it matters: Understanding how mitochondrial-targeted therapies influence the tumor microenvironment is crucial, as AML relies on oxidative phosphorylation and can suppress immune responses through metabolic competition.
• What they did: Researchers developed IMP125, a potent ClpP agonist, and demonstrated its ability to selectively inhibit mitochondrial respiration in AML cells, leading to microenvironmental changes that restore T-cell activity, especially when combined with PD-1 blockade.
• The result: IMP125's dual action not only directly kills AML cells but also reprograms the immune environment, enabling T-cell recovery and suggesting a combined therapeutic approach that bridges mitochondrial targeting and immunotherapy.